Latest Industry Insights

To learn more about some of the ways that companion diagnostics can benefit oncology patients, Technology Networks spoke to Dr Luca Quagliata, Global Director of Medical Affairs for Clinical NGS and Oncology at Thermo Fisher Scientific.

Two teams of scientists in Italy have collaborated on a project that further analyzed the SARS-CoV-2 genome from locally acquired samples. Technology Networks spoke with Professor Stefano Menzo, virologist, and Dr. Valerio Onofri, geneticist, affiliates of the Department of Excellence of Biomedical Science and Public Health, Marche Polytechnic University in Ancona, to learn more about the findings.

Technology Networks recently spoke to David O’Reilly, PhD, Director of Scientific Research at BAT to learn more about the tobacco plant “biomanufacturing factories” that are being used to develop a COVID-19 vaccine. We also discuss the challenges faced when developing a vaccine and the benefits tobacco plants offer compared to conventional vaccine development methods.

Technology Networks recently spoke with Ofer Sharon, CEO of OncoHost, to learn more about ways to overcome patient resistance to immunotherapy and how proteomic profiling in oncology can aid diagnosis, prognosis and treatment of this incredibly complex disease.

Lab efficiency is critical to speeding up development processes, yet many researchers find they spend more time managing consumables data than working at the bench. Lab informatics is one solution to this problem.

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.

Technology Networks recently spoke with Dr Jacques Ravel (Chief Scientist of LUCA Biologics) and Luba Greenwood (CEO of LUCA Biologics) to learn more about what the vaginal microbiome is, how it can contribute to human pathology and the development of novel therapeutics in this space that are approaching clinical trials.

What barriers still exist to the full implementation of next-generation sequencing (NGS) in the diagnostics space, and how can we remove them? Technology Networks recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific, to learn more.

Technology Networks recently spoke with LifeArc’s CEO Melanie Lee, PhD, CBE. Melanie elaborates on LifeArc's mission, discusses the importance of bridging the gap between "bench" and "bedside", and highlights how genomics can help drive earlier intervention.

Technology Networks spoke with GenapSys to learn more about the sequencer which is "100x smaller and less expensive than legacy high-throughput sequencers" and how it can be applied to study the Coronavirus.